|
GELCLAIR® is a bioadherent oral gel with a mechanical action which
provides pain relief by adhering to the mucosal surface of the
mouth, soothing oral lesions of various etiologies such as
medication, disease, radiotherapy, chemotherapy, irritation due to
oral surgery, ageing and traumatic ulcers caused by braces and
ill-fitting dentures. Gelclair is also indicated for diffuse
aphthous ulcers.
Patients with oral lesions - in particular mucositis due to
treatment with chemotherapy or radiotherapy - tend to be debilitated
and in poor general health. The pain and discomfort associated with
oral mucositis may interfere with the ability to eat and drink and
with the planned therapeutic scheme. Anything offering rapid,
symptomatic relief, which would also help patients to eat and drink
more easily, is much needed, in order to improve patients’ quality
of life.
GELCLAIR® has been developed to meet these requirements. It contains
the barrier-forming ingredients polyvinylpyrrolidone (PVP) and
sodium hyaluronate, which form a thin adhesive layer over the oral
mucosa when GELCLAIR® is rinsed within the mouth. This barrier
shields exposed or sensitised nerve endings from overstimulation
during eating, drinking, speaking or even at rest. GELCLAIR® has
been shown to reduce pain and help patients to eat and drink more
easily. (see 'supporting data' for more information).
If you have any questions, please
click
here
Gelclair is classed as a CE Medical Device
The
information contained on this website is for licensing purposes
only.
Legal
Statement
Some information provided in this Website may relate to medical, health or
fitness conditions, their prevention and treatment. This information is
provided for information only. It is not, and is not meant to be, a
substitute for advice that should be provided by a physician or other
medical professional. Do not use, and Helsinn hereby prohibits you from
using, the information for diagnosing a health or fitness problem or
disease. Always consult your own physician and medical advisers.
Click
here to read the full version of legal statement
Last
update
07.04.2008 |
